IPA.US

[HAWKDOG]

Been in this stock for a long time I would be retired if i sold at the peak.  Possible mean reversion happening - company has changed focus to AI in drug discovery.  Could be onto something.
45 million s/o
98 million mc


ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
Join the Discussion:
$IPA.US
-6.49%
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its LENSai™ Immunogenicity Screening can reliably predict Anti-Drug-Antibody (ADA) risk for therapeutic proteins before they enter animal studies or human trials.

"ADA-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars," said Dr. Jennifer Bath, President & CEO, IPA. "With LENSai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-risk programs early and focus resources on the safest molecules."

Late‑stage ADA failures can wipe out $1–2 billion in projected revenue for a single biologic and push launch timelines back 12‑18 months. Yet many programs still lean on time‑intensive lab assays or first‑generation in‑silico screens that look only at peptide‑to‑MHC II binding across a few dozen HLA alleles—leaving large swaths of immune diversity untested and immunogenic "self/non‑self" checks largely unaddressed.

LENSai's HYFT‑powered, alignment‑free immunogenicity screening compresses that entire workflow into one overnight run. It evaluates nearly 900 HLA variants and performs a whole‑proteome "humanness" scan at residue resolution, instantly flagging hot‑spots that legacy tools miss. By revealing design‑level fixes before expensive animal studies or repeat GMP production, the platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods.

Study Highlights

217 marketed and clinical-stage antibodies analyzed – the largest public ADA dataset to predict immunogenicity risk
Single composite score tracks clinical reality – enables reliable ADA incidence risk classification; a score ≥ 54 flags high-risk candidates (> 30 % ADA in patients). The discriminative capability is very powerful as indicated by an AUC=0.92.
Alignment-free, HYFT-powered engine – the proprietary screening algorithm combines state-of-the-art MHC II binding with IPA's proprietary HYFT® patterns, enabling whole-proteome humanness assessment without multiple-sequence alignments.
Detailed amino acid and epitope-level immunogenicity "self" scanning – quickly pinpoints immunogenic hot-spots and suggests sequence edits before expensive wet-lab assays.
Read the full case study: [link]

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology.

[HAWKDOG]

Financial Highlights:

Achieved strong revenue for Fiscal Year 2025 of $24.5 million

Delivered highest-ever fourth quarter revenue of $7.0 million

Reported record fourth quarter Adjusted EBITDA of ($0.3) million, reflecting improved operating efficiency

Achieved fourth quarter gross margin of 64%, up from 48% from Q4 FY24

BioStrand segment grew over 180% in Fiscal year 2025 and had gross margins approaching 90%

BioStrand currently represents over 5% of total annual revenue this year, up from less than 2% in Fiscal Year 2024

 
Recent Corporate Highlights:

The Company's LENSai™ platform demonstrated that it's in silico epitope mapping achieves results on previously unseen antibody–antigen complexes with results that are on par with gold-standard X-ray crystallography—yet delivering structural insights in hours instead of weeks.

An important breakthrough using the Company's HYFT®-powered LENSai platform, as it identified a highly conserved epitope across all four dengue virus serotypes, a key milestone toward developing a potential universal dengue vaccine. Subsequently announced in silico data supporting the vaccine candidate's safety and its ability to activate a balanced immune response.

IPA's AI-designed GLP-1 peptides outperformed or matched semaglutide in independent receptor activation studies, further validating the Company's HYFT-driven LENSai platform.

Entered a strategic USD $8–10 million partnership with a publicly traded biotechnology company focused on the discovery and development of antibody-drug conjugates and bispecific antibodies for potential oncology therapeutics.

Realigned internal R&D strategy to focus on launching an AI-powered therapeutic pipeline, reinforcing IPA's shift toward a bio-native AI drug discovery model.

ImmunoPrecise subsidiary signed material transfer agreement with Biotheus (now BioNTech), for the transfer and evaluation of antibody assets for bispecific tumor-targeting.

Successfully engineered antibodies in silico to a challenging tumor target using LENSai, advancing IPA's vision for accessible, next-generation therapeutics.

Appointed industry veteran Jon Lieber to its Board of Directors, bringing over 30 years of strategic leadership across biotech, capital markets, and public company governance, further strengthening IPA's financial oversight and commercial execution.

Named Jeff Fried, a recognized healthcare data visionary, to its Advisory Board. Fried has played a key role in advancing IPA's AI platform capabilities, particularly the integration of vector search to support large-scale, AI-driven discovery within LENSai ecosystem.

Regained compliance with Nasdaq minimum bid price requirement, reflecting strengthened investor confidence and continued alignment with strategic listing standards.

"Fiscal 2025 was a record-setting year for IPA across multiple dimensions," said Dr. Jennifer Bath, ImmunoPrecise Antibodies CEO. "We delivered strong annual and record fourth quarter revenues, significantly improved gross margins, and achieved one of our strongest adjusted EBITDA performances in the Company's history, with a loss of only $316,000. This reflects our continued progress toward profitability while accelerating innovation through our HYFT-powered LENSai platform. Our BioStrand segment alone grew by more than 180% in Fiscal 2025, highlighting the strength of our AI-driven pipeline. These results underscore the growing commercial validation of our technology, our strategic collaborations, and our ability to deliver real-world impact through next-generation antibody discovery and therapeutic design."

[HAWKDOG]

Nice run this week, no idea why.